CCL21 and gastric cancer: CCL21 has been found to be overexpressed in patients with gastric cancer, and further studies have shown that it upregulates the expression of MALAT1, activates the mTOR signaling pathway, and promotes migration, invasion, and epithelial–mesenchymal transition (EMT) of gastric cancer cells (141).